Cytokines, interferons and toxicities in chemotherapy (07/26/2011)
(...) Gamma interferon is made by T lymphocytes and natural killer cells being an integral component of the immune response. Interferons influence the immune system by binding to some cell surface receptor and inducing a cascade of biologic events. Interferons have antiviral characteristics: they are able to protect an infected cell from invasion by another virus and may indirectly inhibit viral DNA replication, which hinders multiplication of the virus with other cells. (...)

Interleukins in chemotherapy and cancer treatment (07/26/2011)
(...) IL-2 plays a job in both humoral and cell-mediated immunity. In 1992, a recombinant type of IL-2 was approved by the FDA for that treatment of renal cell carcinoma. In 1998, it had been approved for that treatment of adults with metastatic melanoma. (...)

Patient and family education for biotherapy in cancer treatment (07/26/2011)
(...) Patients should be provided all of the necessary materials for self-administration. Nurses must review all possible negative effects and symptom management with patients. Patients should be reassured that most toxicities are dose-, route-, or schedule-dependent and therefore are reversible once the treatment is discontinued. (...)

Preventing chemotherapy errors for maximum patient safety (07/26/2011)
(...) The course describes a didactic content along with a clinical practicum required to prepare the nurse to look after patients undergoing chemotherapy in various settings. Orders are verified by a minimum of two medical professionals, preferably one RN and one pharmacist. This requires a make sure of the patient's name, drug, dose calculation, route, frequency, total daily dose, and date of administration. (...)

Routes of administration for chemotherapy in cancer patients (07/26/2011)
(...) A pro-drug is really a chemical precursor of the active agent that must be changed into an energetic agent being effective. The conversion is accomplished by one or more enzymes found in the liver, tumor sites, or any other tissues. Prodrugs are viewed to supply more selective and intensive therapy for that target tumor. (...)

Minimizing contact with chemotherapeutic agents (07/26/2011)
(...) The recommendations produced by these advisory bodies function as guidelines; institutional policies for chemotherapy handling, administration, and disposal can vary. Nurses should be acquainted with their institution's policies and operations and employ these phones minimize their exposure. Eye contact: Immediately rinse the affected eye or eyes with copious levels of water not less than fifteen minutes. (...)

Cutaneous toxicity issues during chemotherapy (07/26/2011)
(...) The chemotherapy cutaneous reactions range from the following: Alopecia Acral erythema Hyperpigmentation Nail changes Photosensitivity Radiation enhancement and recall ... (...)

Handling hyperpigmentation during chemotherapy (07/26/2011)
(...) Measure the patient's baseline skin ailment and evaluate their skincare regimen. Assure the individual that hyperpigmentation will resolve in time. Ask the individual about concomitant medications that is going to influence skin reactions. (...)

Nausea and vomitong as a side effect of chemotherapy (07/26/2011)
(...) It's postulated that emesis is induced by stimulation of the true vomiting center, the nucleus tractus solitarius, located in the general area of the lateral reticular formulation of the fourth ventricle. The physiologic stimulation of the TVC is mediated by neurotransmitters, including serotonin, dopamine, norepinephrine, and histamine. The receptor sites of these transmitters can be found in the chemoreceptor trigger zoneand the GI tract. (...)

Managing mucositis in the chemotherapy patient (07/26/2011)
(...) Because hematologic malignancies are more common in younger patients, the result is that stomatitis often occurs in patients younger than Two decades old. Patients receiving combination chemotherapy, radiation treatment, antimicrobials, and corticosteroids are in the best risk. Patients who consume alcohol and smoke tobacco will also be at high-risk. (...)

Constipation emerged as a result of chemotherapy (07/26/2011)
(...) Help the individual begin a daily bowel regimen. Let the patient to improve their intake of foods rich in fiber and bulk and also to drink 8 to 10 portions of fluids daily. Warm fluids and prune juice are of help. (...)

Myelosuppression during chemotherapy for various cancers (07/26/2011)
(...) The bone marrow provides the pluripotent stem cells, the precursors towards the main blood components, including erythrocytes, leukocytes, and platelets. Myelosuppression is caused by the destruction of those circulating progenitor cells, which depletes the amount of circulating mature blood cells. This reduction causes the blood count to decrease. (...)

Neutropenia and chemotherapy in cancer treatment (07/26/2011)
(...) In the cancer patient, infection could be life-threatening, particularly when complications for example sepsis occur. Fever may be the first and in certain cases the only real sign; therefore, other tests for example chest x-rays and cultures are essential to verify detecting infection. The white blood cell count nadir is reached in 7 to Fourteen days; recovery occurs in 14 to 4 weeks. (...)

Why fatigue is a normal side effect of chemotherapy (07/26/2011)
(...) Assure the individual that the fatigue is really a side-effect of the chemotherapy and doesn't indicate treatment failure. Get yourself a fatigue profile by asking concerning the patient's fatigue pattern, the start of fatigue, the impact of fatigue with their life and day to day activities, and factors that might bring about their education of fatigue. Help the individual be realistic for activity, rest, and sleep after evaluating their energy. (...)

Neurotoxicity problems during chemotherapy (07/26/2011)
(...) The blood-brain barrier determines whether a cytotoxic agent can get to the nervous system. It blocks some agents from entering the system in a cellular level. Penetration of the CNS differs from that of the peripheral nervous system. (...)

Care for the patient receiving vesicant chemotherapy (07/26/2011)
(...) Verify for adequate blood return before proceeding using the treatment. For peripheral lines, make sure the patency of the vein by feeling for any bruit across the venous track having a 10-mL normal saline IV push. Don't pinch the IV tubing to check on patency. (...)

What chemotherapy is and how it is used in cancer treatment (07/25/2011)
(...) Induction: This term is often used in the treatment of hematologic malignancies. It refers back to the utilization of usuallya mixture of high-dose drugs to induce an entire response when initiating a curative regimen. Intensification: After complete remission is achieved, exactly the same agents employed for induction receive at higher doses, or different agents receive at high doses to effect a better cure rate or perhaps a longer remission. (...)

Cancer cell characteristics and how chemotherapy fights them (07/25/2011)
(...) This can be a constant percentage of the final amount of malignant cells present. If your tumor containing 1 million cells is subjected to a drug that includes a 90% cell kill rate, the first chemotherapy dose will destroy 90%, or 900,000, of the cancer cells. The 2nd dose will kill another 90% of the remaining cells, and 10,000 cells can survive. (...)

Mitotic inhibitors and camptothecins in chemotherapy (07/25/2011)
(...) Taxanes cause mitotic arrest by forming abnormal spindle fibers and mitotic asters. Camptothecins Camptothecins really are a new subcategory of cell cycle-specific drugs. They act in the S phase and inhibit topoisomerase I, a nuclear enzyme essential for maintaining DNA structure. (...)

What is combination chemotherapy how does it fight cancer (07/25/2011)
(...) Many regimens in current use have shown to boost the response rate by 2 to 4 times. Two or more drugs could be given simultaneously or in sequence. The response rates and survival rates are more dramatic simply because they accomplish the next: Maximum cell kill inside the selection of toxicity tolerated by the host. (...)

Monoclonal antibodies and their role in chemotherapy (07/25/2011)
(...) Monoclonal antibodies may be used alone or in in conjunction with cytotoxic agents, toxins, radioisotopes, or biologic agents. Unconjugated mAbs show antitumor activity in many studies. The FDA has approvedtwo unconjugated mAbs for that treatment of cancer. (...)